Fig. 5a,b.

Challenge of Id-specific TCR-transgenic mice with Id⁺ MOPC315 cells has two outcomes. a When a low dose (1.6×10⁵) of tumor cells is injected, immunosurveillance is effective and most mice reject the tumor inoculum [9, 18, 36]. b When a high dose (2×10⁶ cells) is injected, more mice develop tumors and fewer are protected. With progressive tumor growth, Id-specific T cells are deleted in the thymus [37], in peripheral lymphoid organs, and in the tumor itself [2]